- Sponsored Content
Optimal Time to Market for Life-Saving Biopharmaceuticals
August 10, 2020
Sponsored by Rentschler Biopharma
Rentschler Biopharma is an international contract development and manufacturing organization (CDMO) dedicated to biopharmaceutical development and biomanufacturing for over 40 years. We are leading experts with an exceptional track record of over 100 different therapeutic protein formats. As a world-class solution provider, we ensure optimum time to proof-of-concept for clinical stages I and 2, as well as time to market for products in clinical stage 3. By accelerating timelines under consideration of economically attractive process options, we generate a competitive advantage for our clients, with no compromises regarding product quality and safety.
Fill out the form below to read the complete capabilities review now.
You May Also Like